Pembrolizumab Secures FDA Approval in Stomach Cancer

The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab (Keytruda®) for use in patients with advanced gastric (stomach) cancer that is PD-L1 positive.

from Cancer via ola Kala on Inoreader http://ift.tt/2yH4a9S
via IFTTT